The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity
Open accessAbstract
BACKGROUND & AIMS: Bile acids (BAs) are major regulators of hepatic BA and lipid metabolism but their mechanisms of action in non-alcoholic fatty liver disease (NAFLD) are still poorly understood. Here we aimed to explore the molecular and biochemical mechanisms of ursodeoxycholic acid (UDCA) in modulating the cross-talk between liver and visceral white adipose tissue (vWAT) regarding BA and cholesterol metabolism and fatty acid/lipid partitioning in morbidly obese NAFLD patients. METHODS: In this randomized controlled pharmacodynamic study, we analyzed serum, liver and vWAT samples from 40 well-matched morbidly obese patients receiving UDCA (20 mg/kg/day) or no treatment three weeks prior to bariatric surgery. RESULTS: Short term UDCA administration stimulated BA synthesis by reducing circulating fibroblast growth factor 19 and farnesoid X receptor (FXR) activation, resulting in cholesterol 7α-hydroxylase induction mirrored by elevated C4 and 7α-hydroxycholesterol. Enhanced BA formation depleted hepatic and LDL-cholesterol with subsequent activation of the key enzyme of cholesterol synthesis 3-hydroxy-3-methylglutaryl-CoA reductase. Blunted FXR anti-lipogenic effects induced lipogenic stearoyl-CoA desaturase (SCD) in the liver, thereby increasing hepatic triglyceride content. In addition, induced SCD activity in vWAT shifted vWAT lipid metabolism towards generation of less toxic and more lipogenic monounsaturated fatty acids such as oleic acid. CONCLUSION: These data demonstrate that by exerting FXR-antagonistic effects, UDCA treatment in NAFLD patients strongly impacts on cholesterol and BA synthesis and induces neutral lipid accumulation in both liver and vWAT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Triglyceride accumulation protects against fatty acid-induced lipotoxicity
Listenberger, L. L., Han, X., Lewis, S. E., Cases, S., Farese, R. V., Ory, D. S., & Schaffer, J. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630588100 · Cited by 2,075
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
Nonalcoholic fatty liver disease
Adams, L. A. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.045232 · Cited by 1,610
Molecular Basis for Feedback Regulation of Bile Acid Synthesis by Nuclear Receptors
Lu, T. T., Makishima, M., Repa, J. J., Schoonjans, K., Kerr, T. A., Auwerx, J., & Mangelsdorf, D. J. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00050-2 · Cited by 1,487
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c
渡辺, 光., Houten, S. M., Wang, L., Moschetta, A., Mangelsdorf, D. J., Heyman, R. A., Moore, D. D., & Auwerx, J. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421025 · Cited by 1,397
Postic, C., & Girard, J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34275 · Cited by 1,204
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931 · cited 2×
“Notably, this mechanism distinguishes UDCA from highly potent FXR agonist obeticholic acid recently proven beneficial in NASH [29,30].”
Self-citationExpression cloning and characterization of a novel adipocyte long chain fatty acid transport protein
Schaffer, J. E., & Lodish, H. F. (1994) · Cell · doi:10.1016/0092-8674(94)90252-6 · Cited by 872
Shimomura, I., Bashmakov, Y., Ikemoto, S., Horton, J. D., Brown, M. S., & Goldstein, J. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.13656 · Cited by 793
Biochemical and physiological function of stearoyl-CoA desaturase
Paton, C. M., & Ntambi, J. M. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90897.2008 · Cited by 741
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial
Lindor, K. D., Kowdley, K. V., Heathcote, J. E., Harrison, E. M., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., & Colin, P. (2004) · Hepatology · doi:10.1002/hep.20092 · Cited by 727 · cited 3×
“Clinical studies with UDCA in NAFLD have generated results raising questions about therapeutic mechanisms of BAs: While two randomized placebo-controlled trials did not show overall histological improvement including ballooning and inflammation [9,10], a recent high-dose UDCA study attenuated hepatic IR [11].”
Horton, J. D., Shimomura, I., Brown, M. S., Hammer, R. E., Goldstein, J. L., & Shimano, H. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2961 · Cited by 701
Min, H.-K., Kapoor, A., Fuchs, M., Mirshahi, F., Zhou, H., Maher, J., Kellum, J., Warnick, R., Contos, M. J., & Sanyal, A. J. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.004 · Cited by 652
LXRS AND FXR: The Yin and Yang of Cholesterol and Fat Metabolism
Kalaany, N. Y., & Mangelsdorf, D. J. (2006) · Annual Review of Physiology · doi:10.1146/annurev.physiol.68.033104.152158 · Cited by 615
Enoch, H. G., Catalá, A., & Strittmatter, P. (1976) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)33223-4 · Cited by 558
Acyl‐coenzyme A:cholesterol acyltransferases
Chang, T.-Y., Li, B.-L., Chang, C. C. Y., & Urano, Y. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90926.2008 · Cited by 443
Kars, M., Yang, L., Gregor, M. F., Mohammed, B. S., Pietka, T. A., Finck, B. N., Patterson, B. W., Horton, J. D., Mittendorfer, B., Hotamisligil, G. S., et al. (2010) · Diabetes · doi:10.2337/db10-0308 · Cited by 400
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
Ratziu, V., de Ledinghen, V., Oberti, F., Mathurin, P., Wartelle-Bladou, C., Renou, C., Sogni, P., Maynard, M., Larrey, D., Serfaty, L., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.030 · Cited by 338
MARSCHALL, H., WAGNER, M., ZOLLNER, G., FICKERT, P., DICZFALUSY, U., GUMHOLD, J., SILBERT, D., FUCHSBICHLER, A., BENTHIN, L., & GRUNDSTROM, R. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.009 · Cited by 325
Self-citationLeuschner, U. F. H., Lindenthal, B., Herrmann, G., Arnold, J. C., Rössle, M., Cordes, H., Zeuzem, S., Hein, J., & Berg, T. (2010) · Hepatology · doi:10.1002/hep.23727 · Cited by 317
Sato, H., Macchiarulo, A., Thomas, C., Gioiello, A., Une, M., Hofmann, A. F., Saladin, R., Schoonjans, K., Pellicciari, R., & Auwerx, J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7015864 · Cited by 298
FATP1 Is an Insulin-Sensitive Fatty Acid Transporter Involved in Diet-Induced Obesity
Wu, Q., Ortegon, A. M., Tsang, B., Doege, H., Feingold, K. R., & Stahl, A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.9.3455-3467.2006 · Cited by 296
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
Claudel, T., Inoue, Y., Barbier, O., Duran-Sandoval, D., Kosykh, V., Fruchart, J., Fruchart, J.-C., Gonzalez, F. J., & Staels, B. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00896-5 · Cited by 268
Self-citationThe Farnesoid X Receptor Controls Gene Expression in a Ligand- and Promoter-selective Fashion
Lew, J.-L., Zhao, A., Yu, J., Huang, L., de Pedro, N., Peláez, F., Wright, S. D., & Cui, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306422200 · Cited by 213
Roda, A., Minutello, A., Angellotti, M., & Fini, A. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42614-8 · Cited by 199
Trauner, M., & Graziadei (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00596.x · Cited by 159
Self-citationNilsell, K., Angelin, B., Leijd, B., & Einarsson, K. (1983) · Gastroenterology · doi:10.1016/s0016-5085(83)80003-1 · Cited by 159
The Diversity of Health Effects of Individual trans Fatty Acid Isomers
Gebauer, S. K., Psota, T., & Kris‐Etherton, P. M. (2007) · Lipids · doi:10.1007/s11745-007-3095-8 · Cited by 155
Impact of visceral adipose tissue on liver metabolism
Lafontan, M., & Girard, J. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2008.04.001 · Cited by 143
Dilger, K., Hohenester, S. D., Winkler–Budenhofer, U., Bastiaansen, B. A. J., Schaap, F. G., Rust, C., & Beuers, U. H. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.014 · Cited by 113
Ellis, E. C. S., Axelson, M., Abrahamsson, A., Eggertsen, G., Thörne, A., Nowak, G., Ericzon, B., Björkhem, I., & Einarsson, C. (2003) · Hepatology · doi:10.1002/hep.1840380419 · Cited by 103
Self-citationHepatic cholesterol metabolism in human obesity
Ståhlberg, D., Rudling, M. J., Angelin, B., Björkhem, I., Forsell, P. K. A. L., NILSELL, K., & Einarsson, K. (1997) · Hepatology · doi:10.1002/hep.510250623 · Cited by 99
Liu, J., Lü, H., Lu, Y., Lei, X., Cui, J. Y., Ellis, E. C. S., Strom, S. C., & Klaassen, C. D. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu151 · Cited by 94
Cited by
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism
Wahlström, A., Sayin, S. I., Marschall, H.-U., & Bäckhed, F. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.005 · Cited by 2,851
Self-citationDietary lipids, gut microbiota and lipid metabolism
Schoeler, M., & Caesar, R. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09512-0 · Cited by 1,163
Gut microbiota and intestinal FXR mediate the clinical benefits of metformin
Sun, L., Xie, C., Wang, G., Wu, Y., Wu, Q., Wang, X., Liu, J., Deng, Y., Xia, J., Chen, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0222-4 · Cited by 1,011
Chávez-Talavera, O., Tailleux, A., Lefebvre, P., & Staels, B. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.055 · Cited by 970
Gut-liver axis: Pathophysiological concepts and clinical implications
Tilg, H., Adolph, T. E., & Trauner, M. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.017 · Cited by 843
Self-citation
Metadata
- Authors
- Mueller, M., Thorell, A., Claudel, T., Jha, P., Koefeler, H., Lackner, C., Hoesel, B., Fauler, G., Stojakovic, T., Einarsson, C., Marschall, H.-U., & Trauner, M.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2015-06
- Volume
- 62
- Issue
- 6
- Pages
- 1398-1404
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2063009130
- Cited by
- 312
- References
- 39
- FWCI
- 19.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.